Vicarious Surgical (RBOT) Projected to Release Earnings on Thursday

Vicarious Surgical (NYSE:RBOT) is anticipated to announce its Q2 2026 resultson Thursday, July 30th. Analysts expect Vicarious Surgical to announce earnings of ($1.15) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Vicarious Surgical Stock Down 1.9%

Shares of Vicarious Surgical stock opened at $0.11 on Tuesday. The stock’s 50-day simple moving average is $0.40 and its 200-day simple moving average is $1.03. Vicarious Surgical has a 52 week low of $0.10 and a 52 week high of $11.46. The company has a market capitalization of $765,830.00, a price-to-earnings ratio of -0.01 and a beta of 1.88.

Institutional Trading of Vicarious Surgical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Vicarious Surgical in the 4th quarter worth approximately $27,000. Dimensional Fund Advisors LP raised its position in shares of Vicarious Surgical by 22.1% during the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock valued at $110,000 after buying an additional 3,615 shares during the last quarter. Connective Capital Management LLC bought a new stake in shares of Vicarious Surgical during the third quarter valued at approximately $169,000. Geode Capital Management LLC lifted its holdings in shares of Vicarious Surgical by 26.0% in the fourth quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after buying an additional 8,344 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Vicarious Surgical during the fourth quarter worth $98,000. Institutional investors own 47.27% of the company’s stock.

About Vicarious Surgical

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.